Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.

@article{Zhao2015EstablishmentAB,
  title={Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.},
  author={Bao-Xia Zhao and Jing Wang and Bo Geun Song and Hong Wei and Wei-Peng Lv and Li-min Tian and Mei Li and Shen Juan Lv},
  journal={Molecular medicine reports},
  year={2015},
  volume={11 4},
  pages={
          2767-74
        }
}
Non‑small cell lung cancer (NSCLC) cells harboring mutations in the epidermal growth factor receptor (EGFR) gene initially respond well to EGFR tyrosine kinase inhibitors (TKI), including gefitinib. However the tumor cells will invariably develop acquired resistance to the drug. The EGFR T790M mutation is generally considered to be the molecular genetic basis of acquired TKI resistance. The present study aimed to explore how the T790M mutation induces tumor cells to escape inhibition by TKI… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2011

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008

Similar Papers

Loading similar papers…